Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Alkermes ( (ALKS) ) has issued an update.
Alkermes announced significant advancements in its orexin agonist program, particularly with its ALKS 2680 candidate, expected to provide pivotal data in 2025. The company, boasting a strong financial position with over $1 billion in expected product sales, sees substantial opportunities for value creation as it leads in innovative treatments for hypersomnolence disorders, potentially reshaping the market with its upcoming studies and regulatory strategies.
More about Alkermes
Alkermes is a biopharmaceutical company specializing in the development and commercialization of central nervous system (CNS) medicines. It is recognized for its proprietary commercial products and robust pipeline, particularly in the field of neuroscience, with a strong focus on disorders like narcolepsy and idiopathic hypersomnia.
YTD Price Performance: -2.33%
Average Trading Volume: 1,654,930
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.54B
See more insights into ALKS stock on TipRanks’ Stock Analysis page.
